07/31/2026 06:30
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy

Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN)....

07/31/2026 10:05
AngloGold Ashanti Q2 30 June 2026 Earnings Release and Dividend Declaration

AngloGold Ashanti plc (“AngloGold Ashanti”, “AGA”, the “Company” or the “Group”) said Q2 2026 free cash flow* rose 36% year-on-year to $727m, further strengthening its balance sheet and providing for increased shareholder returns. The Company reaffirmed its 2026 annual guidance.(6) This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731433108/en/ “This result shows the strong cash generation capacity of our assets, and the resilience ...

07/31/2026 11:42
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 2026

2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2026...

Subscribe to